Vertex, FDA
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex Pharmaceuticals ( VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings. But Vertex now is showing that it also can be a game changer when it comes to treating one of the most common of health problems -- pain.
Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...
The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...
BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself ...
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback